AG Mednet has signed the master services agreement with Biovisiq, a Japanese imaging core laboratory, (ICL) to provide zero-delay clinical trial solutions to Asian pharmaceutical market.
The AG Mednet Submission Quality and Compliance module will detect errors that result in query stoppages and offer ICLs a system to check information, automatically update support systems and minimise queries returned for correction or re-scanning.
In clinical trials conducted using AG Mednet technology, sponsors experience more than 75% query reduction rate, resulting in significant cost savings and faster decision times, according to the company.
Biovisiq president and CEO Shigeto Ogawa said that the company provides reliable, cost-effective and compliant imaging services to Japan and the growing Asian pharmaceutical market.
"We are confident that our partnership with AG Mednet will help accomplish this goal," Ogawa added.
More than half of all image-related clinical trial query stoppages result from preventable human errors that can delay a trial for up to seven weeks, according to industry research.
AG Mednet president and CEO Abraham Gutman said, "As clinical trials move closer to the patient base across Asia, we look forward to working with the talented team at Biovisiq to make a significant contribution to the Asia and Japan-specific drug discovery and development markets."
